Condition: Metastatic Colorectal Cancer · Sponsor: Sun Yat-sen University
The primary aim of phase II CEIL study is to evaluate the efficacy of cetuximab and envafolimab plus mFOLFOXIRI versus cetuximab plus mFOLFOX6 as first line treatment of patients with initially unresectable and previously untreated RAS/BRAF wild-type, MSS, left-side metastatic colorectal cancer(mCRC), in terms of Progression-free Survival.
This description comes directly from the study's public registry record.
Yanhong Deng, Ph.D · 86-13925106525 · 13925106525@163.com
Xiaoyu Xie, M.D. · 86-13570487315 · xie_xyu@163.com
Always discuss trial participation with your own doctor first.
| The First People's Hospital of Foshan | Foshan, Guangdong, China | Recruiting |
| The Sixth Affiliated Hospital of Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| Affiliated Cancer Hospital of Guizhou Medical University | Guiyang, Guizhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05959356